focu urolift/growth outlook
manag upbeat call wasnt surpris given perform quarter sale come
constant currenc basi adjust one less sell day sale growth driven urolift
contribut growth also rest portfolio moreov manag comment revenu rais
basi driven urolift remaind product underscor broad-bas natur perform
et ersu surpris ov higher perhap littl
surpris agnitud giv en believ expect sale guidanc rais mention earlier
note first look sale mix yield non-oper ep beat guidanc bit mix due fx think
thing bull big top line beat cc adjust sell day growth lead higher full year cc sale
guid higher urolift sale quarter guide-up abil off-set greater headwind bear oper margin weaker
guidanc reduc ep rais albeit larg fx driven high expect already/valu howev surpris
thought bull like win top-lin etric ore focu day arket hard
like adjust constant currenc growth num ber ev en without adjustm ent increm ental
inv estm ent spend seem ake differ
full note coupl takeaway
urolift focu call expect urolift perform well expect balanc year
beyond manag continu feel confid abil drive growth rais full year expect approx
approx note continu target japan launch mid-to-l revenu contribut
manag note japanes contribut wasnt long-rang plan discuss last year
sale guidanc rais constant currenc sale guidanc rais manag note revenu
rais basi driven urolift remaind product note guidanc impli rate
ytd revenu manag also note year mid-point new guidanc growth
urolift come
op argin guidanc reduc ep unchang manag note increment headwind fx full year ep
versu prior estim offset higher revenu contribut oper margin guidanc reduc
prior rang addit fx impact oper margin increment headwind sinc
last updat manag note higher sell expens out-performance urolift proactiv invest compani
make includ upgrad qualiti system strengthening/protect ip posit enhanc custom experi ep also help
lower interest expens tax rate come lower end previou rang
lrp reaffirm ed manag re-affirmed lrp target organ sale growth gross margin oper margin
repla ezpla fda ask som addit data thu manag note abl submit
file previous expect provid updat test take sever quarter manag
note million revenu product lrp
reach question
kstew note earn call verbatim
 posit acceler momentum report basi constant currenc
normal one less ship day constant currenc grow th
strength top line broad base driven improv everi global product categori grow th intervent urolog
vascular access surgic intervent access
particularli strong grow th america asia respect
gross margin op margin ep ith latter repres y/i grow th
ep perform slightli better expect despit greater fx headw ind normal fx adjust ep
incred pleas ith revenu quarter manag increas guidanc constant currenc basi
grow th grow th addit base strong urolift perform ytd increas guidanc
approx approx
pleas increas revenu expect driven urolift non-urolift product breakdow compon rais
basi driven urolift remaind product
also reaffirm gross margin guidanc low ere oper guidanc larg due fx decis make grow th
infrastructur invest due revenu low er interest expens off-set fx impact reaffirm ep rang
pleas ith expect grow ep hile fund invest offset fx tariff
revenu geographi growth rate cc basi
america revenu ere driven intervent urolog vascular access product
emea revenu ere quarter grow th led intervent urolog vascular access product
perform slightli low er anticip due time certain order look forw ard expect perform improv vs
asia revenu ere grow th strongest surgic vascular access busi china strength
korea se asia
oem revenu ere grow th led sutur cathet offer full year basi expect upper singl digit rang
ever due difficult comp time order expect grow th flat vs prior year
revenu product categori growth rate cc basi
vascular access revenu driven cvc picc ez-io saw increas distributor order posit
impact result revers de-stock
intervent access revenu ere strength broad-bas grow th complex cathet biolog on-
control iab meaning driver grow th manta three month limit releas gone ell strong posit feedback
kol continu conduct price discoveri market track ith strategi gener posit physician patient
experi expect meaning contribut
anesthesia revenu ere dow due soft airw ay pain manag product
repla updat ill refer ez-pla track approv process expect complet bla
cours commun ith fda recent receiv addit question previous anticip other
requir addit analysi test hich ill take time complet longer expect bla time due
uniqu natur product import understand revenu assum guidanc less
lrp estim share last year move forw ard ith fda ill provid updat hen receiv
inform submiss associ regulatori time
surgic revenu ere grow th driven ligat surgic instrument perform ell also
easi comp
intervent urolog sale increas excel progress drive adopt urolift expect train new
urologist patient demand dtc program perform ell drive patient talk urologist urolift
expect roll-out latter half full convers expect also continu prep market urolift japan mid
late ith revenu ramp meaning given out-performance rais intervent urolog grow th
approx approx
oem revenu ere grow th led sutur cathet offer full year basi expect upper singl digit rang
ever due difficult comp time order expect grow th flat vs prior year
respiratori urolog revenu ere cc basi driven increas sale bladder manag off-set
declin respiratori
clinic reimburs updat
pleas announc revis surgic mi bph revis coverag urolift coverag nation
region plan bsbc medicar last larg commerci payor reimburs team focus
support ith real-w orld data ill take time ork channel uplift expect due
revenu grow th incred strong lead manag increas guidanc year ork build product portfolio
achiev grow th gross margin mid-point approxim expect grow th urolift nearli
remaind busi mid-point constant currenc rang indic approx grow th
difficult comparison give manag confid grow multi-year period despit difficult comparison
expect materi improv adjust gross oper margin
adjust gross profit adjust gross margin expans primarili reflect increas sale
volum cost improv mix partial offset fx tariff logistic/distribut cost inflat
oper margin dow improv gm off-set fx sell expens relat revenu upsid upgrad
qualiti protect ip enhanc custom experi fx neutral ould flat vs year ago
interest expens dow year ago due cost currenc sw ap agreement
tax vs year ago increas primarili due mix earn reduc stock base comp
ep ere y/i includ headw ind fx neutral basi also includ tariff expens
headw ind divestitur hich contribut prior year
cfo ere decreas y/i due conting consider payment
reduc debt net leverag
given perform ytd expect balanc increas constant currenc guidanc
manag also increas report revenu grow th fx expect
headw ind revenu prior
reaffirm gross margin rang low ere oper margin rang ere oper margin target expect
oper margin prior rang reduct full year expect due less favor fx
environ manag project margin impact fx addit vs previou guidanc margin also impact
higher sell expens ith out-performance urolift proactiv invest compani make includ upgrad
interest expens last call point low end rang ever libor trend favor includ reduct
low ere guidanc
tax reaffirm rang although expect low end rang
full year dilut share count expect prior
acceler grow th broad base invest pay dividend underli constant currenc strong ytd increas ep
adjust tariff ytd
question arrang topic
urolift japan outlook chang think alw ay though latter part reimburs approv
sale noth chang us market japanes market market origin lrp didnt anticip revenu
japan see potenti upsid market dont see signific differ betw een us japan
stage see collabor relationship ith japanes us urolog associ ith mani japanes urologist aua
everi year continu build relationship urologist know ell clip call point know ell ould look
grow ould look someth men health space ould interest
urolift train physician observ train doc year said train far
avail seen urologist spectrum becom champion move fast follow er clinic
sale earli adopt real orld data ipp score reduct qol improv cathet rate cathet free
urolift aua last quarter clinic data favor reimburs event quarter one
lead charg alw ay said clinic data patient outcom ill day eek tw ice sunday urolift
better clinic data reimburs issu ith competitor hasnt flush either ont come fruition later
 hat drive product better patient reimburs ell almost everi life cover us ell
 ay treatment bph
dtc urolift benefit top line uptick hen see advertis campaign urologist defin best path
transit urolift go take long main reason dont ant disrupt grow th ant
thought roll-out
impli guidanc back half year margin expans come fx understood
larger fx impact due balanc sheet revalu saw increas op margin back half
sequenti oper expans driven higher gm driven better oper expens leverag gross
margin gener manufactur cost improv benefit restructur product/geograph mix hile expect modest
increas opex expect increas revenu revenu drive leverag incur
oper expens trade show invest ip portfolio cost strengthen better profit ork
done understand driver need take place
chang trajectori lower rate comp easier comp comparison grew
 hich tougher comp realli confid even tougher comp environ next year oem ia came quick
 didnt expect maintain grow th posit side see perhap anesthesia emea could better take
urolift continu incred ell continu invest behind
manta first three month success what feedback reiter materi revenu what hold
back would contribut look like begin us limit market releas get posit feedback line
 ith clinic data publish show ing short time hemostasi also see reduct major complic test site
high reorder rate hich prove product sticki get valu committe ithout much
pushback reason signific uptick revenu product divestitur time vein
reprocess busi ell hold
repla ez-pla think time manufactur infrastructur alreadi built enough address
militari demand signific portion civilian demand ez-pla collabor ith fda construct parti
excit unchart ater product like never approv addit test
appropri give updat time line test done next sever quarter hen back
provid updat fda ork ith militari ell ill give updat subsequ call
price manta percuv what take environ regard manta ould come price
yet gener price uniqu med-tech compani insofar intern disciplin price posit rang
 hich get ytd continu see strength portfolio disciplin commerci organ
percuv updat limit market releas ill come extend limit fuller market releas everyth
come closer plan
surgic vascular took big step forward talk momentum back half year pleas
 ith quarter vascular first quarter de-stock distributor saw re-stock anticip day
adjust vascular ytd expect vascular mid-singl rang tougher comp back half year vascular
grow th posit grow th come picc take share ez-io vidacar surgic good
easier comparison last year dow anniversari exit trocar see perform ell in-lin ith
broad thought leverag give posit transact dealshow see environ
capac scale transact find capac dont urgenc financi disciplin ill
futur transact ill benefit sharehold environ littl frothi good qualiti asset
alw ay frothi not-so-good asset never stop look activ market place
invest make spend go timelin payoff incred happi ith first six
month lrp strategi ork iu greater ia almost apac grew vascular greater
oem greater updat guidanc today first year lrp pull forw ard invest
 ork strategi ork hen see return increas revenu carri expens ith commiss thing
reoccur follow ing year base commiss follow ing year set anticip good solid posit deliv
outlin lrp couldnt happier revenu grow th key driver strategi ork
growth deliv strong result histor rang wide look full year increas rang
grow th come ex-urolift grow th year midpoint expect urolift come
end custom trace ent slight de-stock re-stock also rang ith urolift
ad
intervent access iab busi seem move part market datascop recal impella
side see headwind ere aw competitor recal product mani instanc capit equip ouldnt
expect see massiv benefit iab busi continu solid solid pleas ith grow th
new pump market recal ouldnt flow ed continu take share ith new pump solid
grow th america emea also asia feel good
ip strengthen smaller compani believ might infring ill protect valid right product
allow copi cat certain market significantli reinforc ip make sure file number new product pipelin
excit tri get broad coverag product ill come market
launch someth similar guidelin seen ill address ith appropri respons
market growth take share ent variou segment vascular access
market rang take share ithin picc part portfolio also ez-io intervent access almost
that share gain that market surgic market intervent urolog creat new categori
take pharma anoth area oem take share anesthesia isnt take share grow ing modestli market
de-stock didnt quit come back
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
